The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and potentially unreliable paper-based ...

AI’s true power lies in pattern recognition across messy, real-world data: Natural language processing extracts phenotypes, comorbidities, and device usability feedback from unstructured clinical ...

Data content management will drive the growing global data and analytics market in the pharmaceutical sector, which will reach a valuation of $2.1bn by 2028, according to a report. The 2024 edition of ...

Life sciences industry has regulatory compliance at the center of all its operations, so maintaining the integrity of data has always been a pressing need for this industry globally. Regulators such ...

In an industry where speed and precision can directly affect patient outcomes, pharma companies are under pressure to ...

The volume of raw data collected during clinical research is ever-growing—modern clinical trials "generate an average of 3.6 million data points" from regular site visits, labs, procedures, ...

Proactive documentation using AI reviews all patient data to reduce clinician burden and enhance care quality and efficiency.

Join Dell Technologies for an engaging webinar and Q&A session on Driving Better Business Outcomes with a Data-Centric Approach in Pharma. During this session, we will delve into the world of ...

Pharma’s finally catching up: real-time data is helping teams move faster, stay compliant and deliver better care where it counts. In the rapidly evolving pharmaceutical and healthcare landscape, ...

DUBLIN--(BUSINESS WIRE)--The "Efficient Batch Record Design and Review" training has been added to ResearchAndMarkets.com's offering. This online training is designed for professionals in the ...

When it comes to bringing life-saving therapeutics to market, the first significant investment for pharmaceutical companies is within research and development, which includes drug discovery, drug ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...